The Beatrice Hunter Cancer Research Institute CRTP Integrated Learning Session (ILS) will be held on Thursday 23 January from 10:00am-12:00pm AST in room 2L7, 2nd floor, Tupper Building Link, Dalhousie University and by videoconference to the following sites:
- Dalhousie Halifax – Tupper Medical Building, Second floor Tupper Link – 2L3
- Georges Dumont Hospital - Salle de vidéoconférence-Centre de sante du sein – local 171.33
- MUN – Meeting room 3 (HSC 2985)
- Dalhousie Truro –Student Learning Commons – SLC Boardroom
- UNB St. John – LRC 266
- CBU- B260-A
- Acadia – BAC144A
Integrated Learning Sessions consist of presentations from various cancer research perspectives to better understand and address a topic. ILS sessions are mandatory for CRTP Trainees – please contact email@example.com if you are unable to attend. Trainees recognize the benefit of having supervisors in attendance at these sessions and we hope that all supervisors of CRTP trainees will attend as many sessions as possible.
Topic: Personalized Medicine
Precision Medicine – What About Cancer Radiotherapy Tailored Treatments?
Jean-Philippe Pignol, MD, PhD
Professor in Radiation Oncology
Department Chair & Head
I am an MD in Radiation Oncology and a PhD in Nuclear Physics from the University Louis-Pasteur in Strasbourg, France. I initially worked in France from 1994 to 2000 as Radiation Oncologist at the Institut Gustave-Roussy in Paris and the Centre Antoine-Lacassagne in Nice. I joined the University of Toronto in 2000 and worked as a breast cancer specialist at the Sunnybrook Odette Cancer Centre. My research in Toronto received over $14M in funding over 14 years, with half coming from peer review funding agencies. Research included the evaluation of nanoparticle radiosensitization energy deposition and the development of targeted moieties. In clinical research our team made the national news after publishing the benefit of breast IMRT and on a new one hour breast cancer treatment using radioactive seeds brachytherapy. In August 2014, I joined the Department of Radiation Oncology, Erasmus University in Rotterdam, as Professor and Chair with a cross appointment at the Technical University of Delft. I also became Medical co-Director of HollandPTC, one of the four protontherapy initiatives in The Netherlands. I led several research programs, focusing on reducing the number of treatments using ultra-high precision robotic radiotherapy and also the development of thermobrachytherapy based on radioactive nanoparticles. To this end we received over $30M in research funding. In April 2018, I joined the Radiation Oncology department at Dalhousie University.
Exercise and Cancer, More Than 150 Minutes
Scott Grandy, PhD
School of Health and Human Performance
Cross appointed with the Department of Pharmacology Affiliate Scientist,
Division of Cardiology, NSHA Dalhousie University
Dr. Grandy is an Associate Professor in the School of Health and Human Performance (Kinesiology) and Pharmacology at Dalhousie University as well as an affiliate scientist in the Division of Cardiology (Nova Scotia Health Authority) and an associate scientist with the Beatrice Hunter Cancer Research Institute. His research focuses on the relationship between heart disease and cancer. Specifically, he is interested how cancer treatments, such as chemotherapy, lead to increased risk of heart disease in cancer survivors. Scott’s research also examines how exercise can be used to protect the heart from cancer therapies as well as how it can be used to decrease the side-effects associated with cancer treatment. He currently co-leads a clinical exercise program for cancer patients/survivors called Activating Cancer Communities through and Exercise Strategy for Survivors (ACCESS).
Overview of Cancer Immunotherapy: Focus on Immune Checkpoint Inhibitors
Sheila Drover, PhD
Associate Professor of Immunology
Memorial University of Newfoundland
Dr. Sheila Drover is an Associate Professor in Immunology, Division of BioMedical Sciences at Memorial University, St. John’s. Research in the Drover laboratory is primarily focused on immune profiles and immune modulation in human breast cancer. Their early work revealed patients had a better outcome if their tumor cells expressed certain types of histocompatibility molecules, contained large numbers of infiltrating CD4+T-cells and expressed high levels of IFN-γ. However, cancer cells are known to escape immune destruction partly due to upregulation of inhibitory or checkpoint molecules such as PD-1 and LAG3 on immune cells and PD-L1 on cancer cells. Thus, our current work is focused on two areas 1) investigating the mechanism of deregulated IFN-γ and HLA pathways in HER2-positive breast cancer and 2) immunomodulation of HLA and PD-L1 on cancer cell lines using small kinase inhibitors and targeted immune therapeutics.
Funding for Dr. Drovers’ research has come from various sources: Medical Research Foundation Awards at Memorial University, Canadian Breast Cancer Research Alliance, Medical Research Council, CIHR and RDC, Canadian Breast Cancer Foundation, (Atlantic Chapter).
If you are unable to attend a session via the videoconference locations listed above, please contact firstname.lastname@example.org at least 48 hours prior to the session date for other connection options.
PLEASE NOTE: It is important to mute mics when not in use so that background noise is minimal. For technical support during sessions, please phone: 1-855-265-7142